This infection can be particularly serious in older patients and requires targeted antibiotic treatment. Rapid, specific diagnosis is essential.
Chlamydia pneumoniae DNA
Chlamydia pneumoniae DNA
Studies have shown that lower respiratory tract infections account for ~10% of all adult admissions to acute care hospitals. Chlamydia pneumoniae bacteria are one such cause.
Individuals infected with C. pneumoniae are generally asymptomatic. In symptomatic cases, infection most commonly present with a cough, fever, headache, and malaise. However, they can also develop laryngitis, pharyngitis, coryza and pneumonia. Initial symptoms have a gradual onset but can persist over extended periods of time and some may experience a continuous cough and malaise for several weeks or months, despite antimicrobial therapy.
C. pneumoniae is spread from person-to-person through respiratory droplets. It can also spread through contact with objects contaminated with respiratory droplets as the bacteria can survive on surfaces for up to 30 hours. C. pneumoniae is associated with a long incubation period of 3-4 weeks. with a period of infectivity ranging from 2-14 days.
Nasopharyngeal swabs (NPS) placed in up to 3 mL of viral transport media, bronchoalveolar lavage (BAL) or sputum (collected in a sterile universal container). Lower respiratory samples are the preferred sample type for Chlamydia pneumonia.
|Coronavirus (229E, HKU1, NL63, OC43)||Bordetella pertussis|
|Human Metapneumovirus||Mycoplasma pneumoniae|
|Influenza A (H1, H3, H1-2009)|
|Parainfluenza Virus (PIV-1, PIV-2, PIV-3, PIV-4)|
|Respiratory Syncytial Virus|
In addition to the packaging of samples, the transport/delivery of clinical samples to the laboratory is required to be in adherence to all national regulations for the safe transport of biological materials. Enfer Medical provides a fully compliant logistics service, aligned with clients’ testing requirements.
Prompt transport of specimens:
To ensure prompt testing of samples and release of results within the published test turnaround times, samples should arrive to the laboratory by 18:00. Test turnaround time is measured from receipt of the sample at the laboratory until the time the authorised results are reported to users.
In rare cases specimens may not be suitable for testing on arrival to the laboratory. In that case the sample will be rejected at the receipt stage and the service user will be notified immediately and an explanation as to why the sample could not be processed will be provided. Reasons why samples cannot be processed include but are not limited to:
- Samples received beyond the stability limits and/or not at the correct temperature indicated for each test.
- Incorrect sample type received.
- Leaking samples, sample not received or sample insufficient for analysis as stated below within sample requirements.
- Non-compliant samples or request forms i.e. those missing sample date information, missing sample test request and/or missing sample site/type information.
- Samples received without the necessary patient identifiers.
- NOT DETECTED